Research programme: hepatitis C virus therapies - Kemin PharmaAlternative Names: KPE-00001113
Latest Information Update: 21 Aug 2007
At a glance
- Originator Kemin Pharma; National Institutes of Health (USA); Rega Institute for Medical Research
- Class Carbohydrates
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Hepatitis C
Most Recent Events
- 15 Jan 2004 Preclinical trials in Hepatitis C treatment in Belgium (unspecified route)